Reata's Bardoxolone Promises Renal Benefits In Alport Syndrome
Another Positive Read-Out For A Clinical-Stage Reata Drug
Reata is moving ahead with commercial plans as its potential first-in-class Nrf2 activator, bardoxolone methyl, meets primary and secondary endpoints in a first-year interim analysis of the Phase III CARDINAL study in patients with Alport syndrome, an inherited form of chronic kidney disease (CKD).
You may also be interested in...
News and highlights of applications submitted for US FDA approval, from the Pink Sheet’s FDA Performance Tracker
Chinook launched less than two years ago to develop precision medicines for chronic kidney diseases and will have three drugs in the clinic in 2021, including a Phase III candidate for IgA nephropathy.
Lantern, Avidity, Generation Bio and Vaxcyte launched initial public offerings during the second week of June as biopharma continues to intrigue IPO investors. Also, Blackstone invested $350m in Reata's bardoxolone and Checkmate’s $85m series C led recent VC deals.